Ukrain, a plant derived semi-synthetic compound, exerts antitumor effects against murine and human breast cancer and induce protective antitumor immunity in mice

Experimental Oncology

Volumn 34, Issue 4, 2012, Pages 340-347

  Bozeman, E N ^a   Srivatsan, S ^a   Mohammadi, H ^b   Daniels, D ^a   Shashidharamurthy, R ^a   Selvaraj, P ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNESAW STATE UNIVERSITY   (United States)

Author keywords

Anticancer drug; Breast cancer; Cytotoxicity; Protective immunity; Ukrain

Indexed keywords

CASPASE; CONCANAVALIN A; LIPOCORTIN 5; TRYPAN BLUE; UKRAIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; STAINING; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BERBERINE ALKALOIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PHENANTHRIDINES; PHYTOTHERAPY;

EID: 84872417832     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Murphy SL, Xu J, Kochanek KD. Deaths: Preliminary Data for 2010. Natl Vital Stat Rep 2012; 60:1-52.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
3. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
4. von der Maase H. Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumour. Radiother Oncol 1986; 7: 47-68.
5. National Cancer Institute NIoHDTP. NSC 631570: results of the Human Cell Line Screen.
6. Uglyanitsa KN, Nefyodov LI, Doroshenko YM, et al. Ukrain: a novel antitumor drug. Drugs Exp Clinical Res 2000; 26: 341-56. (Pubitemid 32373368)
7. Hohenwarter O, Strutzenberger K, Katinger H, et al. Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain. Drugs Exp Clin Res 1992; 18: 1-4. (Pubitemid 23118392)
8. Ernst E, and Schmidt K. Ukrain - a new cancer cure? A systematic review of randomised clinical trials. BMC Cancer 2005; 5: 69.
9. Susak YM, Zemskov VS, Yaremchuk OY, et al. Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. Drugs Exp Clin Res 1996; 22: 115-22. (Pubitemid 26336258)
10. Susak YM, Yaremchuk OY, Zemskov VS, et al. Randomised clinical study of Ukrain on colorectal cancer. Eur J Cancer 1995; 31: 153-153(1)
11. Uglyanitsa KN, Nefyodov LI, Brzosko V. Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. Report 1. Clinical aspects of Ukrain application. Drugs Exp Clin Res 2000; 26: 223-30. (Pubitemid 32373347)
12. Sotomayor EM, Rao K, Lopez DM, et al. Enhancement of macrophage tumouricidal activity by the alkaloid derivative Ukrain. In vitro and in vivo studies. Drugs Exp Clin Res 1992; 18: 5-11. (Pubitemid 23118393)
13. Cordes N, Plasswilm L, Bamberg M, et al. Ukrain, an alkaloid thiophosphoric acid derivative of Chelidonium majus L. protects human fibroblasts but not human tumour cells in vitro against ionizing radiation. Int J Rad Biol 2002; 78: 17-27. (Pubitemid 34098347)
14. Heppner G, Miller F, Shekhar P. Nontransgenic models of breast cancer. Breast Cancer Res 2000; 2: 331-4. (Pubitemid 32223615)
15. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-405.
16. Rovero S, Amici A, Di Carlo E, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133-42.
17. Franken NA, Rodermond HM, Stap J, et al. Clonogenic assay of cells in vitro. Nature Protocols 2006; 1: 2315-9.
18. Habermehl D, Kammerer B, Handrick R, et al. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 2006; 6: 14.
19. Mendoza J, Zamora R, Gallardo JC, et al. NF-kappaB does not influence the induction of apoptosis by Ukrain. Cancer Biol Ther 2006; 5: 788-93. (Pubitemid 44775136)
20. Roublevskaia IN, Polevoda BV, Ludlow JW, et al. Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain. Anticancer Res 2000; 20: 3163-7.
21. Roublevskaia IN, Haake AR, Ludlow JW, et al. Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. Drugs Exp Clin Res 2000; 26: 141-7. (Pubitemid 32373338)
22. Zhanaeva SJA, Falameeva OV, Filatova TG, et al. Effect of different biological response modifiers on growth and metastasizing of murine lewis lung adenocarcinoma. Int J Immunother 2003; 29: 141-50. (Pubitemid 39409857)
23. DuPre SA, Hunter KW Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol 2007; 82: 12-24.
24. Gagliano N, Moscheni C, Torri C, et al. Effect of Ukrain on matrix metalloproteinase-2 and Secreted Protein Acidic and Rich in Cysteine (SPARC) expression in human glioblastoma cells. Anticancer Drugs 2006; 17: 189-94.
25. Gagliano N, Pettinari L, Aureli M, et al. Malignant phenotype of renal cell carcinoma cells is switched by ukrain administration in vitro. Anticancer Drugs 2011; 22: 749-62.
26. Lanvers-Kaminsky C, Nolting DM, Koster J, et al. In vitro toxicity of Ukrain against human Ewing tumor cell lines. Anticancer Drugs 2006; 17: 1025-30. (Pubitemid 44454779)
27. Skivka LM, Trompak OO, Kudryavets YI, et al. The effect of NSC-631570 (ukrain) alone and in combination with pathogen-associated molecules on cell cycle distribution and apoptosis induction of mouse melanoma cells with different biological properties. Exp oncol 2010; 32: 92-96.
28. Aschhoff B. Ukrain and hyperthermia treatment in a patient with Ewing's sarcoma (case report). Drugs Exp Clin Res 1998; 24: 241-2. (Pubitemid 29126754)
29. Vyas JJ, Jain VK. Ukrain treatment in carcinoma of the oesophagus (case report). Drugs Exp Clin Res 1996; 22: 267-9. (Pubitemid 26336289)
30. Prokopchuk OL, Zemskov SV, Susak YM. Ukrain treatment of a patient with retroperitoneal synovial sarcoma. Case report. Drugs Exp Clin Res 2000; 26: 255-6. (Pubitemid 32373352)
31. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003; 170: 4905-13. (Pubitemid 36554719)
32. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-701. (Pubitemid 41815875)
33. Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71: 768-78.
34. Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. The EMBO J 2012; 31: 1062-79.
35. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61. (Pubitemid 46067386)
36. Zitvogel L, Kepp O, Senovilla L, et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16: 3100-4.
37. Martins I, Kepp O, Schlemmer F, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-58.
38. Liepins A, Nowicky JW. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570). Drugs Exp Clin Res 1996; 22: 103-13. (Pubitemid 26336257)
39. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-21.
40. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-61.